Compugen Ltd. (NASDAQ:CGEN) Stock Now Rated “Buy” by Wall Street Brokerages

Compugen Ltd. (NASDAQ:CGEN) has been assigned a consensus recommendation of “Buy” from the five research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $5.00.

CGEN has been the subject of several analyst reports. Weiss Ratings upgraded shares of Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Compugen in a research report on Monday, October 12th.

Compugen Stock Performance

Shares of Compugen stock opened at $1.96 on Friday. The business has a 50-day simple moving average of $2.41 and a 200-day simple moving average of $2.43. Compugen has a one year low of $1.43 and a one year high of $3.23. The company has a market cap of $185.32 million, a PE ratio of 5.16 and a beta of 2.78.

Compugen (NASDAQ:CGEN) last released its earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. The firm had revenue of $2.60 million for the quarter, compared to analyst estimates of $1.28 million. Compugen had a net margin of 47.56% and a return on equity of 42.57%. During the same period in the prior year, the firm earned ($0.08) earnings per share. On average, sell-side analysts predict that Compugen will post -0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compugen

Several institutional investors have recently modified their holdings of CGEN. Calamos Advisors LLC acquired a new position in shares of Compugen during the first quarter worth $63,000. Hillsdale Investment Management Inc. purchased a new position in Compugen in the first quarter valued at $68,000. Glenmede Trust Co. NA increased its holdings in Compugen by 187.5% in the first quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 22,500 shares during the last quarter. Squarepoint Ops LLC purchased a new position in Compugen in the second quarter valued at $110,000. Finally, Platform Technology Partners raised its stake in Compugen by 10.0% in the first quarter. Platform Technology Partners now owns 55,000 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 5,000 shares in the last quarter. 12.22% of the stock is owned by hedge funds and other institutional investors.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage biotechnology company focused on developing therapeutics for cancer and other diseases involving the immune system. The company uses computational biology and artificial intelligence-driven approaches to identify potential drug targets and develop antibody-based immunotherapies designed to restore or enhance the immune system’s ability to recognize and attack tumors.

Compugen’s pipeline has included investigational immune checkpoint and immuno-oncology programs, including COM701, an antibody targeting PVRIG, and COM902, an antibody targeting TIGIT.